Ebola outbreak in eastern Congo claims over 100 lives
Translated from Serbian, summarized and contextualized by DistantNews.
At a glance
- Over 100 people have died from Ebola in the eastern Democratic Republic of Congo since an outbreak was declared on May 15.
- The current outbreak involves a rare strain of the virus for which no vaccine or treatment is approved.
- Armed conflicts and attacks on health workers hinder response efforts and disease surveillance.
The eastern Democratic Republic of Congo is grappling with a deadly Ebola outbreak, which has claimed the lives of over 100 individuals since its declaration on May 15. According to the latest reports, 550 cases have been confirmed, resulting in 101 deaths and 19 recoveries. The Ituri province is the most affected, accounting for over 90% of the cases, but the virus has also spread to North Kivu, South Kivu, and crossed the border into Uganda.
This particular outbreak involves a rare strain of the Bundibugyo virus. Unlike the more common Zairean strain of Ebola, there is no approved vaccine or specific treatment for this variant. Experts warn that the actual number of infections is likely higher, as the epidemic was detected late, and the response has been significantly hampered.
Compounding the crisis, health workers face numerous challenges. They are often attacked by dissatisfied local residents and operate with low pay and no rest. Additionally, ongoing armed conflicts with rebel groups impede access to certain areas, further complicating disease surveillance and control efforts. The World Health Organization noted that these conflicts restrict access, disrupt monitoring, and increase the risk of the disease spreading undetected in a region already destabilized by years of conflict involving numerous rebel factions.
Conflicts limit access, disrupt surveillance and increase the risk of undetected spread of the disease.
Originally published by N1 Serbia in Serbian. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.